ATYR
aTyr Pharma, Inc.
Price Chart
Latest Quote
$0.47
+0.03 (+6.05%)
Current Price
| Previous Close | $0.45 |
| Open | $0.44 |
| Day High | $0.47 |
| Day Low | $0.44 |
| Volume | 308,040 |
Stock Information
| Shares Outstanding | 98.05M |
| Total Debt | $11.70M |
| Cash Equivalents | $66.51M |
| Revenue | $190K |
| Net Income | $-70.03M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $46.56M |
| EPS (TTM) | $-0.74 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-11.10M |
| Sales | $190K |
| Income | $-70.03M |
| Book/sh | $0.59 |
| Cash/sh | $0.68 |
| Employees | 58 |
Financial Ratios
| Quick Ratio | 5.73 |
| Current Ratio | 5.78 |
| Debt/Eq | 20.26 |
Returns & Margins
| ROA | -51.79% |
| ROE | -105.63% |
| Operating Margin | -38573.68% |
Ownership
| Insider Ownership | 2.45% |
| Institutional Ownership | 48.55% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.74 |
| P/S | 245.08 |
| P/B | 0.80 |
Analyst Data
| Recommendation | none |
| Target Price | $2.86 |
Technical Indicators
| SMA20 | $0.49 |
| SMA50 | $0.66 |
| SMA200 | $1.01 |
| RSI | 47.94 |
| ATR | 0.0432 |
| Shares Float | 95.51M |
| Short Float | 23.72% |
| Short Ratio | 4.77 |
| Volatility | 0.54 |
| Rel Volume | 0.12 |
Performance History
| Week | +4.14% |
| Month | -5.77% |
| Quarter | -46.16% |
| 6 Months | -38.80% |
| YTD | -37.43% |
| Year | -90.87% |
| 3 Years | -78.41% |
| 5 Years | -89.87% |
| 10 Years | -98.79% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $0.47 | 308,040 |
| 2026-06-16 | $0.45 | 643,200 |
| 2026-06-15 | $0.44 | 1,620,900 |
| 2026-06-12 | $0.44 | 1,425,500 |
| 2026-06-11 | $0.47 | 1,230,500 |
| 2026-06-10 | $0.47 | 969,300 |
| 2026-06-09 | $0.46 | 1,777,000 |
| 2026-06-08 | $0.44 | 1,778,400 |
| 2026-06-05 | $0.47 | 2,784,600 |
| 2026-06-04 | $0.51 | 1,472,700 |
| 2026-06-03 | $0.50 | 1,730,300 |
| 2026-06-02 | $0.52 | 1,936,700 |
| 2026-06-01 | $0.55 | 4,420,200 |
| 2026-05-29 | $0.54 | 5,425,800 |
| 2026-05-28 | $0.49 | 9,861,800 |
| 2026-05-27 | $0.48 | 2,511,900 |
| 2026-05-26 | $0.48 | 2,278,700 |
| 2026-05-22 | $0.49 | 3,180,800 |
| 2026-05-21 | $0.53 | 2,765,200 |
| 2026-05-20 | $0.53 | 3,412,900 |
| 2026-05-19 | $0.48 | 2,876,900 |
| 2026-05-18 | $0.52 | 5,394,200 |
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
đ° Latest News
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
MarketBeat âĸ 2026-05-12T00:09:03Z
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting
MarketBeat âĸ 2026-03-12T12:03:10Z
Atyr Pharma: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-05T21:10:24ZIs aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans?
Simply Wall St. âĸ 2026-01-11T13:51:21Z
Atyr Pharma: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-06T21:48:47ZIndependent Director of aTyr Pharma Paul Schimmel Buys 91% More Shares
Simply Wall St. âĸ 2025-10-12T12:31:00Z
Assessing aTyr Pharma (ATYR) Valuation as Investors Weigh Recent Stock Swings and Future Prospects
Simply Wall St. âĸ 2025-09-17T12:14:14Z
aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail
Clinical Trials Arena âĸ 2025-09-16T11:20:29Z
Social Buzz: Wallstreetbets Stocks Mostly Higher Pre-Bell Tuesday; aTyr Pharma, Oracle to Advance
MT Newswires âĸ 2025-09-16T10:38:16ZSector Update: Health Care Stocks Decline Late Afternoon
MT Newswires âĸ 2025-09-15T19:40:44Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $190,000 | $235,000 | $353,000 | $10,386,000 |
| Operating Revenue | $190,000 | $235,000 | $353,000 | $10,386,000 |
| Expenses | ||||
| Total Expenses | $77,817,000 | $68,149,000 | $55,272,000 | $56,790,000 |
| Other Income Expense | $3,504,000 | $3,892,000 | $4,522,000 | $1,061,000 |
| Other Non Operating Income Expenses | $3,504,000 | $3,892,000 | $4,522,000 | $1,061,000 |
| Operating Expense | $77,817,000 | $68,149,000 | $55,272,000 | $56,790,000 |
| General And Administrative Expense | $17,598,000 | $13,777,000 | $12,979,000 | $13,982,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-74,118,000 | $-64,023,000 | $-50,389,000 | $-45,338,000 |
| Normalized Income | $-74,118,000 | $-64,023,000 | $-50,389,000 | $-45,338,000 |
| Net Income From Continuing And Discontinued Operation | $-74,118,000 | $-64,023,000 | $-50,389,000 | $-45,338,000 |
| Total Operating Income As Reported | $-77,627,000 | $-67,914,000 | $-54,919,000 | $-46,404,000 |
| Net Income Common Stockholders | $-74,118,000 | $-64,023,000 | $-50,389,000 | $-45,338,000 |
| Net Income | $-74,118,000 | $-64,023,000 | $-50,389,000 | $-45,338,000 |
| Net Income Including Noncontrolling Interests | $-74,123,000 | $-64,022,000 | $-50,397,000 | $-45,343,000 |
| Net Income Continuous Operations | $-74,123,000 | $-64,022,000 | $-50,397,000 | $-45,343,000 |
| Pretax Income | $-74,123,000 | $-64,022,000 | $-50,397,000 | $-45,343,000 |
| Operating Income | $-77,627,000 | $-67,914,000 | $-54,919,000 | $-46,404,000 |
| Per Share | ||||
| Diluted EPS | $-0.80 | $-0.86 | $-0.94 | $-1.60 |
| Basic EPS | $-0.80 | $-0.86 | $-0.94 | $-1.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-76,074,000 | $-66,374,000 | $-52,178,000 | $-44,709,000 |
| Reconciled Depreciation | $1,553,000 | $1,540,000 | $2,741,000 | $1,695,000 |
| EBITDA (Bullshit earnings) | $-76,074,000 | $-66,374,000 | $-52,178,000 | $-44,709,000 |
| EBIT | $-77,627,000 | $-67,914,000 | $-54,919,000 | $-46,404,000 |
| Diluted Average Shares | $92,985,359 | $74,261,265 | $53,606,488 | $28,419,569 |
| Basic Average Shares | $92,985,359 | $74,261,265 | $53,606,488 | $28,419,569 |
| Diluted NI Availto Com Stockholders | $-74,118,000 | $-64,023,000 | $-50,389,000 | $-45,338,000 |
| Minority Interests | $5,000 | $-1,000 | $8,000 | $5,000 |
| Research And Development | $60,219,000 | $54,372,000 | $42,293,000 | $42,808,000 |
| Selling General And Administration | $17,598,000 | $13,777,000 | $12,979,000 | $13,982,000 |
| Other Gand A | $17,598,000 | $13,777,000 | $12,979,000 | $13,982,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $67,480,000 | $70,019,000 | $90,658,000 | $71,464,000 |
| Total Assets | $93,003,000 | $96,830,000 | $120,653,000 | $95,786,000 |
| Total Non Current Assets | $12,766,000 | $14,876,000 | $17,661,000 | $14,915,000 |
| Other Non Current Assets | $2,383,000 | $3,017,000 | $3,615,000 | $3,358,000 |
| Current Assets | $80,237,000 | $81,954,000 | $102,992,000 | $80,871,000 |
| Prepaid Assets | $677,000 | $8,093,000 | $2,390,000 | $2,950,000 |
| Receivables | $873,000 | $1,736,000 | $2,436,000 | $11,775,000 |
| Other Receivables | $873,000 | $1,736,000 | $2,436,000 | $11,775,000 |
| Cash Cash Equivalents And Short Term Investments | $78,687,000 | $72,125,000 | $98,166,000 | $66,146,000 |
| Cash And Cash Equivalents | $10,743,000 | $11,055,000 | $22,544,000 | $9,981,000 |
| Cash Equivalents | $7,916,000 | $9,581,000 | $21,626,000 | $8,585,000 |
| Cash Financial | $2,827,000 | $1,474,000 | $918,000 | $1,396,000 |
| Other Current Assets | - | - | - | $2,950,000 |
| Debt | ||||
| Total Debt | $12,033,000 | $13,283,000 | $15,095,000 | $11,534,000 |
| Long Term Debt And Capital Lease Obligation | $10,567,000 | $12,031,000 | $13,767,000 | $10,640,000 |
| Current Debt And Capital Lease Obligation | $1,466,000 | $1,252,000 | $1,328,000 | $894,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $25,715,000 | $26,998,000 | $30,183,000 | $24,502,000 |
| Total Non Current Liabilities Net Minority Interest | $10,567,000 | $12,031,000 | $13,767,000 | $10,640,000 |
| Current Liabilities | $15,148,000 | $14,967,000 | $16,416,000 | $13,862,000 |
| Payables And Accrued Expenses | $13,682,000 | $13,715,000 | $15,088,000 | $12,968,000 |
| Payables | $3,891,000 | $4,323,000 | $3,529,000 | $3,106,000 |
| Accounts Payable | $3,891,000 | $4,323,000 | $3,529,000 | $3,106,000 |
| Equity | ||||
| Common Stock Equity | $67,480,000 | $70,019,000 | $90,658,000 | $71,464,000 |
| Total Equity Gross Minority Interest | $67,288,000 | $69,832,000 | $90,470,000 | $71,284,000 |
| Stockholders Equity | $67,480,000 | $70,019,000 | $90,658,000 | $71,464,000 |
| Gains Losses Not Affecting Retained Earnings | $-8,000 | $-40,000 | $-74,000 | $-433,000 |
| Other Equity Adjustments | $-8,000 | $-40,000 | $-74,000 | $-433,000 |
| Retained Earnings | $-606,164,000 | $-532,046,000 | $-468,023,000 | $-417,634,000 |
| Other | ||||
| Ordinary Shares Number | $98,031,104 | $84,038,922 | $63,286,404 | $29,498,488 |
| Share Issued | $98,031,104 | $84,038,922 | $63,286,404 | $29,498,488 |
| Tangible Book Value | $67,480,000 | $70,019,000 | $90,658,000 | $71,464,000 |
| Invested Capital | $67,480,000 | $70,019,000 | $90,658,000 | $71,464,000 |
| Working Capital | $65,089,000 | $66,987,000 | $86,576,000 | $67,009,000 |
| Capital Lease Obligations | $12,033,000 | $13,283,000 | $15,095,000 | $11,534,000 |
| Total Capitalization | $67,480,000 | $70,019,000 | $90,658,000 | $71,464,000 |
| Minority Interest | $-192,000 | $-187,000 | $-188,000 | $-180,000 |
| Additional Paid In Capital | $673,554,000 | $602,021,000 | $558,692,000 | $489,502,000 |
| Capital Stock | $98,000 | $84,000 | $63,000 | $29,000 |
| Common Stock | $98,000 | $84,000 | $63,000 | $29,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $10,567,000 | $12,031,000 | $13,767,000 | $10,640,000 |
| Current Capital Lease Obligation | $1,466,000 | $1,252,000 | $1,328,000 | $894,000 |
| Current Accrued Expenses | $9,791,000 | $9,392,000 | $11,559,000 | $9,862,000 |
| Net PPE | $10,383,000 | $11,859,000 | $14,046,000 | $11,557,000 |
| Accumulated Depreciation | $-4,828,000 | $-4,542,000 | $-4,621,000 | $-6,354,000 |
| Gross PPE | $15,211,000 | $16,401,000 | $18,667,000 | $17,911,000 |
| Leases | $5,653,000 | $5,653,000 | $5,653,000 | $4,414,000 |
| Other Properties | $3,561,000 | $4,491,000 | $5,839,000 | $5,627,000 |
| Machinery Furniture Equipment | $473,000 | $440,000 | $448,000 | $620,000 |
| Buildings And Improvements | $5,524,000 | $5,817,000 | $6,727,000 | $7,250,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $67,944,000 | $61,070,000 | $75,622,000 | $56,165,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-62,063,000 | $-69,184,000 | $-37,436,000 | $-43,527,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-61,986,000 | $-69,119,000 | $-33,221,000 | $-41,886,000 |
| Cash Flow From Continuing Operating Activities | $-61,986,000 | $-69,119,000 | $-33,221,000 | $-41,886,000 |
| Operating Gains Losses | $-12,000 | $-3,000 | $-6,000 | $-92,000 |
| Investing Activities | ||||
| Capital Expenditure | $-77,000 | $-65,000 | $-4,215,000 | $-1,641,000 |
| Investing Cash Flow | $-5,053,000 | $17,233,000 | $-20,127,000 | $47,245,000 |
| Cash Flow From Continuing Investing Activities | $-5,053,000 | $17,233,000 | $-20,127,000 | $47,245,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $66,423,000 | $40,261,000 | $66,519,000 | $5,472,000 |
| Financing Cash Flow | $66,011,000 | $39,864,000 | $66,230,000 | $5,451,000 |
| Cash Flow From Continuing Financing Activities | $66,011,000 | $39,864,000 | $66,230,000 | $5,451,000 |
| Net Common Stock Issuance | $66,423,000 | $40,261,000 | $66,519,000 | $5,472,000 |
| Common Stock Issuance | $66,423,000 | $40,261,000 | $66,519,000 | $5,472,000 |
| Other | ||||
| Repayment Of Debt | $-539,000 | $-497,000 | $-394,000 | $-66,000 |
| Interest Paid Supplemental Data | $94,000 | $137,000 | $172,000 | $54,000 |
| End Cash Position | $12,978,000 | $14,006,000 | $26,028,000 | $13,146,000 |
| Beginning Cash Position | $14,006,000 | $26,028,000 | $13,146,000 | $2,336,000 |
| Changes In Cash | $-1,028,000 | $-12,022,000 | $12,882,000 | $10,810,000 |
| Proceeds From Stock Option Exercised | $127,000 | $100,000 | $105,000 | $45,000 |
| Net Issuance Payments Of Debt | $-539,000 | $-497,000 | $-394,000 | $-66,000 |
| Net Long Term Debt Issuance | $-539,000 | $-497,000 | $-394,000 | $-66,000 |
| Long Term Debt Payments | $-539,000 | $-497,000 | $-394,000 | $-66,000 |
| Net Investment Purchase And Sale | $-4,988,000 | $17,291,000 | $-15,927,000 | $48,707,000 |
| Sale Of Investment | $88,457,000 | $86,394,000 | $91,050,000 | $90,825,000 |
| Purchase Of Investment | $-93,445,000 | $-69,103,000 | $-106,977,000 | $-42,118,000 |
| Net PPE Purchase And Sale | $-65,000 | $-58,000 | $-4,200,000 | $-1,462,000 |
| Sale Of PPE | $12,000 | $7,000 | $15,000 | $179,000 |
| Purchase Of PPE | $-77,000 | $-65,000 | $-4,215,000 | $-1,641,000 |
| Change In Working Capital | $7,453,000 | $-6,918,000 | $15,012,000 | $-833,000 |
| Change In Other Current Liabilities | $-711,000 | $-343,000 | $2,074,000 | $2,111,000 |
| Change In Payables And Accrued Expense | $-33,000 | $-1,339,000 | $3,262,000 | $6,741,000 |
| Change In Prepaid Assets | $7,334,000 | $-5,638,000 | $622,000 | $2,238,000 |
| Change In Receivables | $863,000 | $402,000 | $9,054,000 | $-11,923,000 |
| Stock Based Compensation | $4,997,000 | $2,989,000 | $2,600,000 | $2,154,000 |
| Amortization Of Securities | $-1,854,000 | $-2,705,000 | $-3,171,000 | $533,000 |
| Depreciation Amortization Depletion | $1,553,000 | $1,540,000 | $2,741,000 | $1,695,000 |
| Depreciation And Amortization | $1,553,000 | $1,540,000 | $2,741,000 | $1,695,000 |
| Depreciation | $1,553,000 | $1,540,000 | $2,741,000 | $1,695,000 |
| Gain Loss On Sale Of PPE | $-12,000 | $-3,000 | $-6,000 | $-92,000 |
| Net Income From Continuing Operations | $-74,123,000 | $-64,022,000 | $-50,397,000 | $-45,343,000 |
| Other Non Cash Items | - | - | - | - |
Fetched: 2026-06-17